近亿元融资！国产血管介入影像一体化平台

Core Viewpoint - Tianjin Hengyu Medical Technology Co., Ltd. has completed nearly 100 million RMB financing, which will be used to advance the research, production, and commercialization of vascular interventional imaging and treatment products, aiming to build a rare integrated platform for vascular interventional diagnosis and treatment in China [1][15]. Market Situation - The global vascular imaging market is experiencing steady growth due to the rising incidence of cardiovascular diseases and the increasing demand for minimally invasive procedures, leading to a significant rise in the need for high-resolution, low-trauma imaging and navigation systems [2]. - In China, the intravascular imaging market has been dominated by foreign brands, but the rise of domestic companies, policy support, and clinical promotion are gradually increasing the localization rate of intravascular imaging devices [2]. - The domestic vascular imaging and interventional systems market is expected to see rapid growth in the coming years, with trends such as AI-enabled imaging analysis and personalized precision intervention reshaping the industry landscape [2]. Company Overview - Hengyu Medical, established in 2016 and headquartered in Tianjin, focuses on intravascular ultrasound (IVUS), optical coherence tomography (OCT), and their derivative multimodal imaging and interventional solutions [5]. - The company possesses a unique capability to master both IVUS and OCT technologies, further developing integrated multimodal imaging systems, which provides a high technical barrier and platform construction advantage [6]. Product Development - Hengyu Medical has been advancing product registration, clinical collaboration, and industrialization verification, forming a series of proprietary intellectual property and production capabilities [8]. - The company has established a complete product matrix covering imaging diagnosis and interventional treatment, including IVUS, OCT, OCT-NIRS, 4D ICE, and laser ablation systems, creating a full-chain layout from imaging acquisition to treatment execution [9]. Technology and Innovation - The IVUS system developed by the company supports real-time intravascular ultrasound imaging, providing accurate assessments of vascular wall structure and plaque burden [11]. - The OCT system utilizes high-speed optical interference technology, achieving micron-level imaging precision, suitable for complex coronary intervention pre-assessment and post-verification [12]. - The OCT-NIRS dual-modal system innovatively combines OCT structural imaging with near-infrared spectroscopy (NIRS) for simultaneous structural and chemical composition analysis, aiding in plaque stability assessment and intraoperative risk evaluation [13]. - The 4D ICE and laser ablation systems enhance procedural navigation and effectively ablate calcified plaques, improving surgical success rates and safety [14]. Conclusion - The recent financing reflects the capital market's ongoing confidence in the domestic vascular interventional imaging and treatment sector, with Hengyu Medical's dual-modal imaging and cross-vascular system layout driving strategic upgrades from cardiovascular to broader vascular applications [15][16]. - In the context of accelerating trends in precision medicine and AI empowerment, Hengyu Medical is poised to become a representative enterprise in the domestic high-end medical imaging equipment field, contributing to the enhancement of China's independent innovation capabilities in vascular interventional diagnosis and treatment [16][17].